CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Carisma Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Carisma Therapeutics Inc
245 1st St Ste 1800
Phone: (617) 444-8550p:617 444-8550 CAMBRIDGE, MA  02142-1292  United States Ticker: CARMCARM
On 3/7/2023, Sesen Bio, Inc. completed a merger with Carisma Therapeutics to form Carisma Therapeutics Inc.
Business Summary
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board SanfordZweifach 67 3/7/2023 3/7/2023
President, Chief Executive Officer, Director StevenKelly 58 3/7/2023 3/7/2023
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Chief Complianc Richard S.Morris 49 3/7/2023 3/7/2023
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Viventia Bio Inc 147 Hamelin St WINNIPEG MB Canada

Business Names
Business Name
CARISMA Therapeutics S.à r.l.
CARM
CTx Operations, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 17 (As of 12/31/2022)
Outstanding Shares: 41,542,534 (As of 3/15/2024)
Shareholders: 17
Stock Exchange: NASD
Federal Tax Id: 262025616
Fax Number: (617) 858-0911
Email Address: info@elevenbio.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024